Lexicon Pharmaceuticals Inc (STU:LX31)
€ 4.096 0 (0%) Market Cap: 275.49 Mil Enterprise Value: 126.67 Mil PE Ratio: 0 PB Ratio: 1.63 GF Score: 52/100

Q2 2019 Lexicon Pharmaceuticals Inc Earnings Call Transcript

Jul 31, 2019 / 12:00PM GMT
Release Date Price: €1.21 (-29.65%)
Operator

Welcome to the Lexicon Pharmaceuticals Second Quarter 2019 Financial Results and Business Update Conference Call. (Operator Instructions) As a reminder, this call is being recorded today, July 31, 2019.

I will now turn the call over to Dr. Kimberly Lee, Head of Investor Relations and Corporate Strategy. Please go ahead.

Kimberly Lee
Lexicon Pharmaceuticals, Inc. - Head of IR & Corporate Strategy

Thank you. Welcome to the Lexicon Pharmaceuticals Second Quarter 2019 Financial Results and Business Update Conference Call. (Operator Instructions) Joining me on today's call are: Lonnel Coats, Lexicon's President and Chief Executive Officer; Alex Santini, Executive Vice President and Chief Commercial Officer; Dr. Pablo Lapuerta, Executive Vice President and Chief Medical Officer; and Dr. Praveen Tyle, Executive Vice President of Research and Development; and Jeff Wade, Executive Vice President of Corporate and Administrative Affairs and Chief Financial Officer.

After our formal remarks, we will open the call up for a Q&A.

Earlier

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot